AP

Applied DNA Sciences IncNASDAQ APDN Stock Report

Last reporting period 30 Jun, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.01

Micro

Exchange

XNAS - Nasdaq

APDN Stock Analysis

AP

Uncovered

Applied DNA Sciences Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-3/100

Low score

Market cap $B

0.01

Dividend yield

Shares outstanding

12.909 B

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 61 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. The company also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.

View Section: Eyestock Rating